Oxaprozin for arthritis

Article Abstract:

The US Food and Drug Administration has approved the drug oxaprozin (Daypro) for the treatment of osteoarthritis and rheumatoid arthritis. Like ibuprofen, oxaprozin is a nonsteroidal anti-inflammatory drug (NSAID). Clinical trials found that 1,200 milligrams (mg) of oxaprozin taken once daily is at least as effective as aspirin in treating rheumatoid arthritis. Also, daily doses of 1,200 mg of oxaprozin appear to be as effective as ibuprofen doses of 1,200 to 1,800 mg in treating rheumatoid arthritis. A 1,200 mg dose of oxaprozin was as effective as 650 mg of aspirin in treating 105 patients with pain for the first four hours after oral surgery and was more effective than aspirin after four hours. Side effects associated with oxaprozin include abdominal pain, nausea and vomiting. As with other NSAIDS, some toxic effects may result from oxaprozin. Information on the effectiveness of oxaprozin is limited, and cheaper alternatives do exist.

Product introduction, Nonsteroidal anti-inflammatory drugs, Nonsteroidal anti-inflammatory agents, Daypro (Medication)

---

New FDA Approvals

Article Abstract:

Celecoxib (Celebrex), a nonsteroidal anti-inflammatory drug (NSAID) used for treatment of osteoarthritis and adult rheumatoid arthritis, has been approved by the FDA. It is the first of NSAIDs that blocks the production of enzyme cyclooxygenase, preventing pain and inflammation. However, it does not block the production of enzyme Cox-1, which helps preserve the stomach lining.

Laws, regulations and rules, Social policy, United States. Food and Drug Administration, Anti-inflammatory drugs, Anti-inflammatory agents, Celecoxib (Celebrex), (Medication)

---

New drugs for rheumatoid arthritis

Article Abstract:

The Food and Drug Administration approved leflunomide, etanercept, and infliximab for the treatment of rheumatoid arthritis. The drugs all block inflammatory processes that contribute to joint damage in the disease. It is not yet known if the drugs will slow the progression of rheumatoid arthritis, or merely relieve the symptoms.

Health aspects, Enbrel (Medication), Remicade (Medication), Arava (Medication)

Similar abstracts:

• Abstracts: HLA typing in families with multiple cases of rheumatoid arthritis. Microheterogeneity of alpha-1 acid glycoprotein in rheumatoid arthritis: dependent on disease duration?
• Abstracts: Euro action on hepatitis B. Protection against hepatitis B. Hepatitis reports available
• Abstracts: Gazing into the future of reform. High stakes for health care
• Abstracts: Pet-borne illness. Pets and you: Companions for health. Activity therapy

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.